Catheter Precision (VTAK) Current Deferred Revenue (2017 - 2026)

Catheter Precision (VTAK) reported Current Deferred Revenue of $126000.0 for Q1 2026, down 92.95% quarter-over-quarter from $1.8 million in Q2 2021.

Catheter Precision (VTAK) Current Deferred Revenue (2017 - 2026) Analysis & Trends

Catheter Precision (VTAK) has 6 years of Current Deferred Revenue data on file, last reported at $126000.0 in Q1 2026.

Current Deferred Revenue for Q1 2026 came in at $126000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $126000.0 (changed N/A YoY), and the FY2020 annual result was $2.5 million, down 24.24% from the prior year.
Current Deferred Revenue slipped to $126000.0 in Q1 2026 per VTAK's latest filing, from $1.8 million in the prior quarter.
Over five years, Current Deferred Revenue peaked at $126000.0 in Q1 2026 and troughed at $126000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn
10	Catheter Precision	921,210.28	109,210.28	390,000.00

Download Data